e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Biological disease markers in airways and parenchymal lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Morphological and immunohistochemical characteristics of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF)
T. Y. Manuilova, E. A. Kogan, E. N. Popova, D. A. Golbin (Moscow, Russia)
Source:
Annual Congress 2002 - Biological disease markers in airways and parenchymal lung disease
Session:
Biological disease markers in airways and parenchymal lung disease
Session type:
Poster Discussion
Number:
3621
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Y. Manuilova, E. A. Kogan, E. N. Popova, D. A. Golbin (Moscow, Russia). Morphological and immunohistochemical characteristics of pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2002; 20: Suppl. 38, 3621
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Morphometric characteristic of pulmonary artery in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2006 - Clinical physiology
Year: 2006
Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease
Year: 2011
Idiopathic pulmonary fibrosis (IPF)
Source: ERS Course 2016
Year: 2016
Prognostic evaluation in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Genetic predictors of idiopathic pulmonary fibrosis (IPF) prognosis
Source: Eur Respir J 2006; 28: Suppl. 50, 830s
Year: 2006
Comparison of clinical characteristics and prognostic factors between combined pulmonary fibrosis and emphysema/UIP versus non-UIP
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006
The similarity and difference of pathology of pulmonary arterioles in COPD and idiopathic lung fibrosis (IPF)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Index of histological activity in idiopathic pulmonary fibrosis (IPF) and chronic interstitial lung diseases (CHILD)
Source: Eur Respir J 2004; 24: Suppl. 48, 533s
Year: 2004
The circulating metabolome in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features
Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases
Year: 2017
Towards a better diagnosis of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2010 - Idiopathic pulmonary fibrosis: present understandings and future directions
Year: 2010
Comparison between the HRCT manifestations of thoracic involvement in collagen vascular diseases (CVD) and idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 225s
Year: 2001
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Pulmonary hypertension is common in end-stage sarcoidosis
Source: Annual Congress 2005 - Progresses in granolomatous lung disease
Year: 2005
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept